On August 8, the website of the Shanghai Stock Exchange showed that the listing application of Frontier Biopharmaceuticals (Nanjing) Co., Ltd. (hereinafter referred to as "Frontier Biologics"), an investment company of New Value Capital, has been approved by the Listing Committee meeting.

According to the prospectus, Frontier Biologics will invest in 1000 projects, including 3 million HIV fusion inhibitors for injection and clinical research and development of Ekonine + 117BNC5 combination therapy.

Founded in 2013, Frontier Biopharmaceutical (Nanjing) Co., Ltd. is an innovative biopharmaceutical company focusing on important therapeutic areas such as HIV antiretroviral therapy and pain.

Among them, the company's self-developed Ebovecton is the first innovative drug (non-generic) for the treatment of AIDS in China, and the second long-acting anti-AIDS new drug in the world, which has been launched in the second half of 2018; The fully injectable long-acting anti-AIDS new drug combination ("ibovirtex + monoclonal antibody 3BNC117") has been approved by the US FDA to enter clinical phase 2 and is expected to enter the market in 2022-2023.

As a leading enterprise of anti-AIDS new drugs in China, Frontier Biotech has undertaken the national "2019th Five-Year Plan" major science and technology project - major new drug creation "AIDS special", in addition, under the background of the new crown epidemic, Frontier Bio has also reached a project cooperation with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences for the development of anti-<>-nCoV new drugs.